Study of BI 1815368 for diabetic macular edema
Treatments studied
Part of Eyes & vision clinical trials.
This trial tests an experimental medication (BI 1815368) given as an eye injection for people with diabetic macular edema, a condition where fluid builds up in the center of the retina and blurs vision. The study aims to see if this new treatment can reduce swelling and improve vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have type 1 or type 2 diabetes, and your blood sugar is relatively stable (HbA1c less than 12%).
- Your eye swelling is in the center of the retina and is at least a certain thickness on an OCT scan.
- Your vision in the study eye is between roughly 20/320 and 20/32 on an eye chart.
- You haven't had certain treatments in the study eye recently, like anti-VEGF injections within the last 4 months (or 6 months for some types), or any laser or steroid treatments in the past year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a new medicine (MK-8748) works as well as or better than the usual treatment (aflibercept) for people with diabetic macular edema, a condition that causes vision loss from diabetes-related swelling in the back of the eye.
This Phase 1 trial tests MS-553 to see how it works and how safely it can be given to people with diabetic retinopathy causing central macular swelling (macular edema). You may be considered if your vision and eye scan results match, and if you can follow frequent study visits.
This study tests different doses of a new medicine (BI 3812465) injected into the eye to treat diabetic macular edema—swelling in the back of the eye caused by diabetes that can blur vision. The trial measures how safe the medicine is and how well patients tolerate it.
This study tests a new drug (RO7823653) given as an eye injection for people with diabetic macular edema, a condition where swelling in the retina harms vision. It aims to see if the drug is safe and how the body processes it.
This trial compares a new treatment (EYP-1901, given as an injection) to a standard injection (aflibercept) for people with diabetic macular edema. It aims to see which works better at reducing swelling and improving vision.
This trial tests an investigational drug called CU06-1004 for people with diabetic macular edema (swelling in the center of the retina caused by diabetes). It aims to see if the drug can improve vision and reduce swelling.
Hear when a new Macular Edema trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.